These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37946367)

  • 1. Role of granulocyte colony stimulating factor in the treatment of cirrhosis of liver: a systematic review.
    Rajpurohit S; Musunuri B; Basthi Mohan P; Bhat G; Shetty S
    J Int Med Res; 2023 Nov; 51(11):3000605231207064. PubMed ID: 37946367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Granulocyte colony-stimulating factor improves survival of patients with decompensated cirrhosis: a randomized-controlled trial.
    Prajapati R; Arora A; Sharma P; Bansal N; Singla V; Kumar A
    Eur J Gastroenterol Hepatol; 2017 Apr; 29(4):448-455. PubMed ID: 27930386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Granulocyte-colony stimulating factor in decompensated liver cirrhosis: a meta-analysis of four randomized controlled trials.
    Dimachkie R; Hamadi R; Alameddine Z; Aridi H; Sakr F; Asmar S; Deeb L
    Eur J Gastroenterol Hepatol; 2023 Dec; 35(12):1382-1388. PubMed ID: 37642669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple cycles of granulocyte colony-stimulating factor in decompensated cirrhosis: a double-blind RCT.
    Venkitaraman A; De A; Verma N; Kumari S; Leishangthem B; Sharma RR; Kalra N; Grover S; Singh V
    Hepatol Int; 2022 Oct; 16(5):1127-1136. PubMed ID: 35322373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple Cycles of Granulocyte Colony-Stimulating Factor Increase Survival Times of Patients With Decompensated Cirrhosis in a Randomized Trial.
    De A; Kumari S; Singh A; Kaur A; Sharma R; Bhalla A; Sharma N; Kalra N; Singh V
    Clin Gastroenterol Hepatol; 2021 Feb; 19(2):375-383.e5. PubMed ID: 32088302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granulocyte Colony-Stimulating Factor Use in Decompensated Cirrhosis: Lack of Survival Benefit.
    Philips CA; Augustine P; Rajesh S; Ahamed R; George T; Padsalgi G; Paramaguru R; Valiathan G; John SK
    J Clin Exp Hepatol; 2020; 10(2):124-134. PubMed ID: 32189927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes after multiple courses of granulocyte colony-stimulating factor and growth hormone in decompensated cirrhosis: A randomized trial.
    Verma N; Kaur A; Sharma R; Bhalla A; Sharma N; De A; Singh V
    Hepatology; 2018 Oct; 68(4):1559-1573. PubMed ID: 29278428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acetyl-L-carnitine for patients with hepatic encephalopathy.
    Martí-Carvajal AJ; Gluud C; Arevalo-Rodriguez I; Martí-Amarista CE
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD011451. PubMed ID: 30610762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Granulocyte colony stimulating factor in decompensated cirrhosis, acute alcoholic hepatitis, and acute-on-chronic liver failure: A comprehensive meta-analysis of randomized controlled trials.
    Di Martino V; Questiaux J; Lemagoarou T; Weil D; Vendeville S; Engelmann C; Hu J; Singh V; Newsome PN; Lal SB; Sarin SK; Berg T; Thevenot T
    Clin Res Hepatol Gastroenterol; 2023 Nov; 47(9):102207. PubMed ID: 37716522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of granulocyte colony-stimulating factor and erythropoietin improves outcomes of patients with decompensated cirrhosis.
    Kedarisetty CK; Anand L; Bhardwaj A; Bhadoria AS; Kumar G; Vyas AK; David P; Trehanpati N; Rastogi A; Bihari C; Maiwall R; Garg HK; Vashishtha C; Kumar M; Bhatia V; Sarin SK
    Gastroenterology; 2015 Jun; 148(7):1362-70.e7. PubMed ID: 25749502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical effectiveness of cell therapies in patients with chronic liver disease and acute-on-chronic liver failure: a systematic review protocol.
    Than NN; Tomlinson CL; Haldar D; King AL; Moore D; Newsome PN
    Syst Rev; 2016 Jun; 5():100. PubMed ID: 27301957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis.
    Goh ET; Stokes CS; Sidhu SS; Vilstrup H; Gluud LL; Morgan MY
    Cochrane Database Syst Rev; 2018 May; 5(5):CD012410. PubMed ID: 29762873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stem cell therapy for dilated cardiomyopathy.
    Diaz-Navarro R; Urrútia G; Cleland JG; Poloni D; Villagran F; Acosta-Dighero R; Bangdiwala SI; Rada G; Madrid E
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD013433. PubMed ID: 34286511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granulocyte-colony stimulating factor in acute-on-chronic liver failure: Systematic review and meta-analysis of randomized controlled trials.
    Martin-Mateos R; González-Alonso R; Álvarez-Díaz N; Muriel A; Gaetano-Gil A; Donate Ortega J; López-Jerez A; Figueroa Tubio A; Albillos A
    Gastroenterol Hepatol; 2023 May; 46(5):350-359. PubMed ID: 36174797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Granulocyte colony stimulating factor: A potential therapeutic rescue in severe alcoholic hepatitis and decompensated cirrhosis.
    Rathi S; Hussaini T; Yoshida EM
    Ann Hepatol; 2021; 20():100211. PubMed ID: 32533952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of cell- and colony stimulating factor-based therapy for liver cirrhosis: a network meta-analysis of randomized controlled trials.
    Sun X; Guo S
    Cytotherapy; 2022 May; 24(5):516-525. PubMed ID: 35227600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study protocol of Phase 2 open-label multicenter randomized controlled trial for granulocyte-colony stimulating factor (GCSF) in post-Kasai Type 3 biliary atresia.
    Nguyen HPA; Ren J; Butler M; Li H; Qazi S; Sadiq K; Dao HT; Holterman A
    Pediatr Surg Int; 2022 Jul; 38(7):1019-1030. PubMed ID: 35391541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. REpeated AutoLogous Infusions of STem cells In Cirrhosis (REALISTIC): a multicentre, phase II, open-label, randomised controlled trial of repeated autologous infusions of granulocyte colony-stimulating factor (GCSF) mobilised CD133+ bone marrow stem cells in patients with cirrhosis. A study protocol for a randomised controlled trial.
    King A; Barton D; Beard HA; Than N; Moore J; Corbett C; Thomas J; Guo K; Guha I; Hollyman D; Stocken D; Yap C; Fox R; Forbes SJ; Newsome PN
    BMJ Open; 2015 Mar; 5(3):e007700. PubMed ID: 25795699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of physical and psychological factors on health-related quality of life in adult patients with liver cirrhosis: a systematic review protocol.
    Polis S; Fernandez R
    JBI Database System Rev Implement Rep; 2015 Jan; 13(1):39-51. PubMed ID: 26447006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.